Table 4.

Reported decision-making based on biopsy findings and willingness to accept risk based on histologic pathology

When examining a procurement biopsy, which of the following scoring systems are used at your center? (N =95)	% (n)
Remuzzi score	21 (20)
Donor Chronic Disease Score (DCDS)	14 (13)
Maryland Aggregate Pathology Index (MAPI)	21 (20)
Chronic Allograft Damage Score (CDI)	7 (7)
Other	3 (3)
We do not use any scoring system in evaluating biopsies	43 (41)

In general, how do biopsies typically affect your acceptance decisions for kidneys with marginal clinical characteristics or donor risk factors? (N =95)	% (n)
A “good” biopsy will often persuade me to transplant a kidney I would consider marginal based on clinical characteristics alone	72 (68)
A “bad” biopsy will often persuade me to decline a kidney with clinical risk factors (e.g., high KDPI)	63 (60)
I obtain the biopsy for extra information but most commonly rely on clinical characteristics for acceptance decisions	22 (21)
Other	4 (4)

In general, how do biopsies typically affect your acceptance decisions for standard criteria kidneys? (N =95)	% (n)
A “good biopsy will often persuade me to transplant a standard criteria kidney	43 (41)
A “bad” biopsy will often persuade me to decline a standard criteria kidney	46 (44)
I obtain the biopsy for extra information but most commonly rely on clinical characteristics for acceptance decisions	37 (35)
Other	7 (7)

How do fibrin thrombi on a biopsy of an otherwise transplantable kidney impact your acceptance decision? (N =95)	% (n)
No influence	19 (18)
If diffuse, likely to decline	63 (60)
If limited, likely to decline	20 (19)
If any present, likely to decline	13 (12)

KDPI, kidney donor profile index.

N = the item denominator, based on number of respondents. Participants were asked to “select all that apply”; thus, column totals may exceed 100%.